Veloxis Sues Intas to Block Copies of Kidney-Transplant Drug

Asahi Kasei Corp.’s Veloxis Pharmaceuticals Inc. alleges that a generic version of Envarsus XR proposed by Intas Pharmaceuticals Ltd.’s Accord Healthcare Inc. infringes six patents for the extended-release tablets, used to prevent organ rejection in kidney transplant patients, according to a federal lawsuit filed in Delaware.

The patents cover oral dosage forms and methods of use and administration of tacrolimus, the drug’s active ingredient, according to a complaint filed Thursday in the US District Court for the District of Delaware. One expires in August 2028 and five expire in May 2028, court filings show.

Veloxis is seeking court orders blocking ...